Boston Scientific wins expanded CE Mark indication to market its Precision Plus spinal cord stimulation system for use in peripheral nerve stimulation as well as for use in patients who need head-only MRIs.
Boston Scientific  (NYSE:BSX ) touted CE Mark approval in the European Union for its Precision Plus spinal cord stimulator, which U.K. regulators also cleared for use during head-only MRI scanning.
The Precision Plus system, the 1st rechargeable implantable pulse generator, delivers electrical pulses that mask pain signals on their way to the brain.
Boston Scientific won FDA approval for the device in 2005 and in Europe and Canada in 2005, and more than 60,000 patients worldwide have been treated with Precision Plus thus far, according to a press release . That represents about 17% of the 350,000 patients worldwide who have received spinal cord stimulation therapy to date, according to Boston Scientific.